Actos metformin

invadergir1   20-Jan-2018 07:34   Комментариев к записи Actos metformin 2

Treating Type 2 Diabetes with Medication - Actos and Other Drugs

Modernizr=function(a,b,c){function C(a)function D(a,b)function E(a,b)function F(a,b)function G(a,b)function H(a,b,d)function I(a,b,c)function J(),s.svg=function(),s.inlinesvg=function();for(var K in s)B(s, K)&&(x=Lower Case(),e[x]=s[K](),v.push((e[x]?

Actoplus MET, Actoplus MET XR Pioglitazone Hcl and Metformin.

Pioglitazone/metformin (also known by the brand names Actoplus Met, Piomet and Politor) is combination of two oral diabetes medications pioglitazone and metformin.

Pioglitazone And <em>Metformin</em> Oral Route Description and Brand.

Pioglitazone And Metformin Oral Route Description and Brand.

Pioglitazone can be used on its own to treat people with type 2 diabetes, particularly overweht people, whose blood sugar is not sufficiently controlled by diet and exercise alone, and who cannot take metformin.

Diabetes Blood Levels - What Are Diabetics

Patients on metformin monotherapy: 15-30 mg/day pioglitazone plus dose of metformin at time of initiating therapy Patients on pioglitazone monotherapy: 1000-1700 mg metformin/day plus dose of pioglitazone at time of initiating therapy Not to exceed 45 mg pioglitazone/2550 mg metformin/day Discontinue metformin at the time of or before an iodinated contrast imaging procedure in patients with an e GFR between 30-60 m L/minute/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinate contrast Temporarily discontinue in patients undergoing radiologic exams using iodinated contrast agents Do not initiate in patients aged ≥80 years Cr Cl demonstrates that renal function is not reduced because these patients are more susceptible to developing lactic acidosis Withhold metformin in presence of any condition associated with hypoxemia, dehydration, or sepsis Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia); lactic acidosis is a medical emergency that must be treated in a hospital setting Pioglitazone may cause fluid retention and cause or exacerbate existing heart failure Edema; thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR) gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin Pioglitazone exerts its antihyperglycemic effect only in presence of insulin; therefore, do not use in type 1 diabetes mellitus or for treatment of diabetic ketoacidosis May cause hypoglycemia; patients receiving therapy in combination with insulin or other antidiabetic medications (particularly insulin secretagogues such as sulfonylureas) may be at risk for hypoglycemia; a reduction in dose of the concomitant antidiabetic medication may be necessary to reduce the risk of hypoglycemia; hypoglycemia can also occur when caloric intake is deficient or when strenuous be necessary to reduce the risk of hypoglycemia exercise is not compensated by caloric supplement; hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs Rare reports of hepatitis and hepatic enzyme elevations to 3 x ULN, including very rare incidences of hepatic failure with and without fatal outcome In controlled clinical trials of metformin, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, reported; certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels; in these patients, routine serum vitamin B12 measurements at two- to three-year intervals may be useful Metformin is substantially excreted by kidney, and risk of metformin accumulation and lactic acidosis increases with degree of renal impairment Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis; therapy is not recommended in patients with hepatic impairment Discuss potential for unintended pregnancy with premenopausal women as therapy with metformin/pioglitazone, may result in ovulation in some anovulatory women Pregnancy: Limited data with metformin/pioglitazone or pioglitazone in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage; poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, still birth and delivery complications; poorly controlled diabetes increases fetal risk for major birth defects, still birth, and macrosomia related morbidity Lactation: There is no information regarding the presence of metformin/pioglitazone or pioglitazone in human milk; effects on breastfed infant, or effects on milk production; there is insufficient information on effects of metformin on breastfed infant and no available information on effects of metformin on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed infant from metformin/pioglitazone or from underlying maternal condition Metformin: Buanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; improves glucose tolerance and lowers both basal and postprandial plasma glucose Pioglitazone: Thiazolidinedione; insulin-sensitizing agent that acts by enhancing peripheral glucose utilization; decreased insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output The above information is provided for general informational and educational purposes only.


Actos metformin:

Rating: 87 / 100

Overall: 98 Rates